Methylsulphonamide, N-ethyl-N-pentyl-

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 有机磺酸及其衍生物
• 英文名称: Methylsulphonamide, N-ethyl-N-pentyl-
• 英文别名: N-ethyl-N-pentylmethanesulfonamide
• 化学式: C₈H₁₉NO₂S
• 分子量: 193.31
• InChiKey: LYAJICLUKDATIT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  12
• 可旋转键数：
  6
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  45.8
• 氢给体数：
  0
• 氢受体数：
  3

文献信息

• AMORPHOUS FORM OF APREMILAST
  申请人：CADILA HEALTHCARE LIMITED

  公开号：US20150283249A1

  公开（公告）日：2015-10-08

  The present invention provides an amorphous form of apremilast and process for preparation thereof. The present invention also provides a pharmaceutical composition comprising an amorphous apremilast and one or more of pharmaceutically acceptable carriers, excipients or diluents used for the treatment of active psoriatic arthritis.

  本发明提供了一种阿普雷米拉斯的非晶态形式及其制备方法。本发明还提供了一种包含非晶态阿普雷米拉斯和一种或多种用于治疗活动性银屑病性关节炎的药用可接受载体、辅料或稀释剂的药物组合物。
• Autophagy Inhibitors
  申请人：MacKeigan Jeffrey Paul

  公开号：US20140148451A1

  公开（公告）日：2014-05-29

  The present invention relates to compounds of formulas III and V that are useful as pharmaceutical agents, particularly as autophagy inhibitors.

  本发明涉及公式III和V的化合物，这些化合物可用作药物制剂，特别是作为自噬抑制剂。
• Forms of apremilast
  申请人：Johnson Matthey Public Limited Company

  公开号：US10196355B2

  公开（公告）日：2019-02-05

  The present disclosure is directed to novel forms of apremilast and pharmaceutical compositions comprising any of the novel forms of apremilast. Also provided are processes for the preparation of novel forms of apremilast.

  本公开涉及新形式的阿普瑞司特和包含任何新形式阿普瑞司特的药物组合物。还提供了制备新型阿普瑞司特的工艺。
• NOVEL FORMS OF APREMILAST
  申请人：Johnson Matthey Public Limited Company

  公开号：US20170362175A1

  公开（公告）日：2017-12-21

  The present disclosure is directed to novel forms of apremilast and pharmaceutical compositions comprising any of the novel forms of apremilast. Also provided are processes for the preparation of novel forms of apremilast.
• US9221760B2
  申请人：——

  公开号：US9221760B2

  公开（公告）日：2015-12-29